Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?

Zacks09-06

A month has gone by since the last earnings report for Allogene Therapeutics (ALLO). Shares have added about 6.4% in that time frame, outperforming the S&P 500. Will the recent positive trend continue...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2465648556?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/e0VWXB5.wUFiKGuJPPpLzg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781","is_english":true,"pubTime":"2024-09-06 23:31","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2465648556","market":"us","top_or_hot":-1,"title":"Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?","media":"Zacks","content":"<div>\n<p>A month has gone by since the last earnings report for Allogene Therapeutics (ALLO). Shares have added about 6.4% in that time frame, outperforming the S&P 500.\nWill the recent positive trend continue...</p>\n\n<a href=\"https://finance.yahoo.com/news/allogene-therapeutics-allo-6-4-153116178.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-06 23:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/allogene-therapeutics-allo-6-4-153116178.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>A month has gone by since the last earnings report for Allogene Therapeutics (ALLO). Shares have added about 6.4% in that time frame, outperforming the S&P 500.\nWill the recent positive trend continue...</p>\n\n<a href=\"https://finance.yahoo.com/news/allogene-therapeutics-allo-6-4-153116178.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALLO","symbol_name":"Allogene Therapeutics Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/allogene-therapeutics-allo-6-4-153116178.html","article_id":"2465648556","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/e0VWXB5.wUFiKGuJPPpLzg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2465648556","pubTimestamp":1725636676,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"A month has gone by since the last earnings report for Allogene Therapeutics . Shares have added about 6.4% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Allogene Therapeutics due for a pullback?Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.Allogene incurred an adjusted loss  of 32 cents per share in second-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 35 cents.Inclusive of impairment charges, the company posted a loss of 35 cents in the second quarter. In the year-ago period, the company reported a loss of 54 cents. No impairment charge was recorded during the year-ago period.ALLO did not generate any revenues during the quarter. In the year-ago period, management recorded revenues worth $0.02 million.General and administrative (G&A) ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ALLO":"Allogene Therapeutics Inc.","INCY":"因塞特医疗"},"translate_title":"Allogene Therapeutics(ALLO)自上次收益报告以来上涨6.4%：还能继续吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLO":1,"INCY":0.9},"content_text":"A month has gone by since the last earnings report for Allogene Therapeutics (ALLO). Shares have added about 6.4% in that time frame, outperforming the S&P 500.\nWill the recent positive trend continue leading up to its next earnings release, or is Allogene Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. \nNarrower Than Expected Loss in Q2, Nil Sales\nAllogene incurred an adjusted loss (excluding impairment of long-lived assets) of 32 cents per share in second-quarter 2024, narrower than the Zacks Consensus Estimate of a loss of 35 cents.\nInclusive of impairment charges, the company posted a loss of 35 cents in the second quarter. In the year-ago period, the company reported a loss of 54 cents. No impairment charge was recorded during the year-ago period.\nALLO did not generate any revenues during the quarter. In the year-ago period, management recorded revenues worth $0.02 million.\nQuarter in Detail\nResearch & development (R&D) expenses were $50.4 million, down 19% from the year-ago quarter’s level.\nGeneral and administrative (G&A) expenses declined 13% year over year to $16.1 million.\nAllogene had $444.6 million of cash, cash equivalents and investments as of Jun 30, 2024, compared with $397.3 million as of Mar 31, 2024. This rise in cash balance is due to the inflow of funds from a secondary issue of common stock worth gross proceeds of around $110 million floated in May 2024. Management claims that the new inflow will help Allogene extend its cash runway into second-half 2026.\n2024 Guidance\nAllogene reiterated its previously issued guidance for 2024. It anticipates incurring operating expenses to be around $300 million for the full year, which includes estimated non-cash stock-based compensation expenses of nearly $60 million. Cash burn for the year is expected to be nearly $200 million.\nHow Have Estimates Been Moving Since Then?\nIt turns out, estimates review have trended upward during the past month.\nThe consensus estimate has shifted 20.86% due to these changes.\nVGM Scores\nCurrently, Allogene Therapeutics has a subpar Growth Score of D, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of F on the value side, putting it in the bottom 20% quintile for this investment strategy.\nOverall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.\nOutlook\nEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Allogene Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.\nPerformance of an Industry Player\nAllogene Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Incyte (INCY), has gained 1.9% over the past month. More than a month has passed since the company reported results for the quarter ended June 2024.\nIncyte reported revenues of $1.04 billion in the last reported quarter, representing a year-over-year change of +9.3%. EPS of -$1.82 for the same period compares with $0.99 a year ago.\nIncyte is expected to post earnings of $1.35 per share for the current quarter, representing a year-over-year change of +22.7%. Over the last 30 days, the Zacks Consensus Estimate has changed -8.3%.\nIncyte has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of D.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAllogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report\nIncyte Corporation (INCY) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2465648556"}